Pharmaceutical exporter to Azerbaijan

AGEMA's working languages are Azerbaijani and Russian. English submissions are technically admissible but require notarised translation of every CTD module, labelling artwork and patient information leaflet, which adds two to three months and meaningful cost to first-time filings. Our standing practice is to prepare Module 1 administrative documents and labelling in Russian from the outset, with Module 3 quality data and Module 2 summaries in Russian or bilingual format. This matches the working habits of AGEMA reviewers and reduces query volume on initial assessment, getting importers to marketing authorisation faster than English-only submissions.

TƏBIB LLC has been the central state buyer for public hospital pharmaceutical supply since the 2019 healthcare reform, replacing facility-by-facility procurement. Tenders are announced through the Single Treasury Account framework with bid windows of three to six weeks, and submissions require AGEMA registration certificate, WHO-format CPP, GMP certificate and price justification annex. We coordinate the full bid through our Baku partner and hold Mumbai-side inventory against allocation calls, so awarded lots ship within the contractual delivery window without scramble production.

Yes. Heydar Aliyev International (GYD) is our primary cold-chain gateway, with weekly consolidations from Mumbai on CEIV Pharma-validated lanes via Azerbaijan Airlines direct and via Doha or Istanbul on partner carriers. We use active or passive temperature-controlled packaging matched to product stability profile, with continuous data-logger monitoring and hand-off to Baku-based 2-8C warehousing. CMR-stability reports are filed with AGEMA upfront, and excursion protocols are documented at SKU level. Vaccines, biosimilars and other 2-8C product move routinely with full chain-of-custody from Mumbai dispatch to importer warehouse receipt.

Azerbaijan is not a member of the Eurasian Economic Union, so EAEU-wide pharmaceutical registrations do not extend to the country. Registration is country-specific through AGEMA, and approvals issued in Russia, Kazakhstan or Belarus do not auto-recognise. That said, Azerbaijani regulatory practice tracks ICH guidance and references Russian Federation State Register data for established molecules, so dossiers prepared for the Russian market need targeted adaptation rather than full reconstruction. We handle this adaptation in-house on the regulatory desk and treat each Azerbaijani filing as a discrete project with its own timeline and renewal cycle.

Our Azerbaijan portfolio centres on oncology, anti-infectives, cardiovascular, diabetes, CNS and cold-chain biologicals. These categories map directly to TƏBIB tender lots and private retail demand patterns. Oncology covers platinum regimens, taxanes, hormonal oncology and biosimilars including trastuzumab and rituximab. Anti-infectives cover beta-lactams, macrolides and third-generation cephalosporins. Cardiovascular covers fixed-dose antihypertensives, statins and oral anticoagulants. We supplement these core ranges with respiratory inhaled products, surgical consumables and named-patient specialty molecules where AGEMA registration and tender allocation justify the workflow.

The Azerbaijani Manat holds a stable peg to the US dollar, which makes USD invoicing the practical default for Indian exports. We invoice in USD with AZN clearing handled at the importer's bank, protecting both sides from FX drift over multi-month dossier-to-dispatch cycles. Standard payment terms include letter of credit confirmed through a Mumbai or Dubai correspondent bank, advance payment with discount for established counterparties, and consignment-stock arrangements with TƏBIB-approved warehouses for high-volume tender allocations. Terms are agreed at master-supply-agreement level rather than line-item, which simplifies operational rollout.

AGEMA timelines for a new generic application typically run nine to fourteen months from submission to marketing authorisation, assuming complete Russian-language dossier and clean responses to expert review queries. Our pre-submission preparation runs eight to twelve weeks for a standard generic with established bioequivalence data, including Russian translation of CTD modules, labelling artwork preparation and notarised Azerbaijani patient information leaflets. End-to-end from project kick-off to first commercial shipment is therefore in the twelve-to-eighteen month band for a single new SKU, with line extensions running faster on the back of the original core dossier.